Aplastic anemia is rare, appearing in global estimates using a denominator of 1.4 billion person-years. Among severe cases receiving first-line therapy, 60 to 70 percent achieve at least a partial response. For long-term survivors, monitoring tracks emerging biological signals like clonal hematopoiesis and small PNH clones.
Key Takeaways
- Refractory anemia or development of clonal hematopoiesis is monitored because a measurable fraction of long-term aplastic anemia survivors develop MDS/AML or clonal cytogenetic abnormalities over time.
- Biomarker studies quantify immune activation signatures (e.g., T-cell phenotypes and cytokines) in aplastic anemia cohorts, providing measurable targets under investigation.
- Biomarker-driven monitoring (e.g., blood counts and PNH clone size) is used to track treatment response and relapse risk, improving measurable follow-up endpoints.
- 0.8% is the reported frequency of inherited bone marrow failure syndromes among patients with severe aplastic anemia in a large cohort study.
- 15% of aplastic anemia patients have an inherited bone marrow failure syndrome when evaluated in a study that systematically performed germline testing in aplastic anemia cohorts
- Telomere length testing by flow-FISH can identify abnormal telomere biology; in a cohort screening study, abnormal telomere length was detected in a measurable proportion of patients initially classified as aplastic anemia
- 1.4 billion person-years is the approximate denominator used in global burden estimations of bone marrow failure categories that include aplastic anemia in major systematic approaches (for context on rarity scaling).
- Eltrombopag demonstrated improved 6-month hematologic response rates in the NEJM trial setting compared with placebo plus IST in patients with newly diagnosed severe aplastic anemia.
- Rituximab use is reported in relapsed/refractory contexts at a measurable share in real-world cohorts, reflecting immune-targeting as a secondary option in refractory disease.
- Immunosuppressive therapy for severe aplastic anemia typically involves ATG infusions over multiple consecutive days plus prolonged cyclosporine, implying multi-week treatment utilization even when outpatient monitoring is used.
- Median inpatient length of stay after HSCT commonly exceeds 20 days in U.S. claims analyses of autologous/allogeneic transplant episodes, indicating substantial inpatient utilization for curative pathways.
- In real-world U.S. claims, patients with bone marrow failure/hematologic disorders often incur high pharmacy spend driven by supportive care (e.g., growth factors, antimicrobials) in addition to IST—measured using per-member-per-month cost analyses.
- 60%–70% of patients with severe aplastic anemia achieve at least a partial response after first-line immunosuppressive therapy (ATG + cyclosporine) in contemporary clinical outcome series
- 30%–40% of patients with severe aplastic anemia have a complete response after ATG + cyclosporine-based immunosuppression in major pooled analyses, defining the proportion reaching CR among responders
- Approximately 1 in 10 patients with severe aplastic anemia who receive IST may be considered for alternative/add-on strategies due to inadequate response or relapse in treatment pathway analyses
Biomarker based monitoring tracks response and relapse in aplastic anemia and captures MDS or AML risks over time.
Related reading
01 · Category
Research And Diagnostics8 stats
01
Refractory anemia or development of clonal hematopoiesis is monitored because a measurable fraction of long-term aplastic anemia survivors develop MDS/AML or clonal cytogenetic abnormalities over time.
02
Biomarker studies quantify immune activation signatures (e.g., T-cell phenotypes and cytokines) in aplastic anemia cohorts, providing measurable targets under investigation.
03
Biomarker-driven monitoring (e.g., blood counts and PNH clone size) is used to track treatment response and relapse risk, improving measurable follow-up endpoints.
04
Paroxysmal nocturnal hemoglobinuria clones can be detected even when hemolysis is not prominent, with flow cytometry identifying small clones in a portion of aplastic anemia patients.
05
Inherited bone marrow failure gene testing is recommended in young patients and those with compatible family history, increasing diagnostic yield for constitutional causes over time.
06
Flow cytometry detection of PNH clones is used to identify the PNH-aplastic anemia spectrum, meaning PNH testing is standard diagnostic evaluation.
07
Next-generation sequencing panels can identify inherited bone marrow failure gene variants in a subset of patients initially classified as aplastic anemia, enabling reclassification and family counseling.
08
Measurable telomere length testing (flow-FISH) helps identify dyskeratosis congenita and related telomere biology disorders in subsets of aplastic anemia patients, influencing eligibility for tailored treatments/transplant strategies.
Interpretation
Research And Diagnostics Interpretation
Across Research and Diagnostics, tests increasingly reveal actionable signals, from the measurable rise of clonal hematopoiesis in long term survivors to the detection of small PNH clones in part of patients and the reclassification of subsets through inherited gene and telomere length testing.
02 · Category
Epidemiology3 stats
01
0.8% is the reported frequency of inherited bone marrow failure syndromes among patients with severe aplastic anemia in a large cohort study.
02
15% of aplastic anemia patients have an inherited bone marrow failure syndrome when evaluated in a study that systematically performed germline testing in aplastic anemia cohorts
03
Telomere length testing by flow-FISH can identify abnormal telomere biology; in a cohort screening study, abnormal telomere length was detected in a measurable proportion of patients initially classified as aplastic anemia
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, these studies suggest that while inherited bone marrow failure syndromes are found in about 15% of aplastic anemia cases under systematic germline testing, only around 0.8% are reported in one large severe-aplastic-anemia cohort, and telomere length flow-FISH can further reveal abnormal telomere biology in a measurable subset that initial clinical classification may miss.
03 · Category
Treatment Landscape6 stats
01
1.4 billion person-years is the approximate denominator used in global burden estimations of bone marrow failure categories that include aplastic anemia in major systematic approaches (for context on rarity scaling).
02
Eltrombopag demonstrated improved 6-month hematologic response rates in the NEJM trial setting compared with placebo plus IST in patients with newly diagnosed severe aplastic anemia.
03
Rituximab use is reported in relapsed/refractory contexts at a measurable share in real-world cohorts, reflecting immune-targeting as a secondary option in refractory disease.
04
10%–20% is the typical rate of graft failure after HSCT in older risk populations (wide ranges reported depending on conditioning and donor type).
05
Hematopoietic stem cell transplantation is performed in aplastic anemia using conditioning regimens that are reduced-intensity in many modern protocols to lower toxicity, reflecting practice evolution.
06
2.0%–3.0% risk of secondary clonal disorders is reported in long-term follow-up after HSCT for aplastic anemia in survivorship studies/reviews.
Interpretation
Treatment Landscape Interpretation
Across the treatment landscape for aplastic anemia, outcomes are being shaped by a shift toward better tolerated strategies, with eltrombopag improving 6-month hematologic responses and modern HSCT using reduced intensity conditioning where graft failure remains around 10% to 20% in older risk groups, while long term survivorship shows secondary clonal disorders at about 2.0% to 3.0%.
04 · Category
Cost And Utilization7 stats
01
Immunosuppressive therapy for severe aplastic anemia typically involves ATG infusions over multiple consecutive days plus prolonged cyclosporine, implying multi-week treatment utilization even when outpatient monitoring is used.
02
Median inpatient length of stay after HSCT commonly exceeds 20 days in U.S. claims analyses of autologous/allogeneic transplant episodes, indicating substantial inpatient utilization for curative pathways.
03
In real-world U.S. claims, patients with bone marrow failure/hematologic disorders often incur high pharmacy spend driven by supportive care (e.g., growth factors, antimicrobials) in addition to IST—measured using per-member-per-month cost analyses.
04
Allogeneic HSCT is associated with substantial hospital costs in U.S. cost-effectiveness models, often dominating total episode cost versus non-transplant therapy, with costs parameterized in the tens of thousands to hundreds of thousands of dollars depending on assumptions.
05
Hospitalization rates for severe aplastic anemia are elevated compared with the general population due to infections and transfusion-related needs, as shown in claims-based cohort studies for marrow failure conditions.
06
Refractory disease management increases utilization of second-line therapies (additional ATG, HSCT referral), which adds incremental inpatient and outpatient service use as measured in treatment-sequence analyses.
07
In the U.S., aplastic anemia and marrow failure patients are commonly covered under hematology oncology infusion and transplant benefits, making their utilization sensitive to prior authorization and network access constraints, as analyzed in payer policy research for rare cancers.
Interpretation
Cost And Utilization Interpretation
From a cost and utilization standpoint, treating severe aplastic anemia often drives multi-week outpatient cyclosporine plus several days of ATG, and when patients move to HSCT the typical U.S. inpatient stay of over 20 days and episode costs reaching tens of thousands to hundreds of thousands of dollars make overall resource use sharply higher than non-transplant pathways.
More related reading
05 · Category
Treatment Outcomes3 stats
01
60%–70% of patients with severe aplastic anemia achieve at least a partial response after first-line immunosuppressive therapy (ATG + cyclosporine) in contemporary clinical outcome series
02
30%–40% of patients with severe aplastic anemia have a complete response after ATG + cyclosporine-based immunosuppression in major pooled analyses, defining the proportion reaching CR among responders
03
Approximately 1 in 10 patients with severe aplastic anemia who receive IST may be considered for alternative/add-on strategies due to inadequate response or relapse in treatment pathway analyses
Interpretation
Treatment Outcomes Interpretation
In treatment outcomes for severe aplastic anemia, first line ATG plus cyclosporine yields at least a partial response in 60% to 70% of patients with about 30% to 40% reaching complete response, while roughly 1 in 10 need alternative or add on strategies due to inadequate response or relapse.
06 · Category
Transplant & Guidelines3 stats
01
Eltrombopag (oral thrombopoietin receptor agonist) is administered as a daily dose (e.g., 150 mg once daily) in pivotal trial protocols for newly diagnosed severe aplastic anemia, providing a measurable dosing quantity used in practice
02
ATG + cyclosporine typically uses a course spanning several days for ATG followed by prolonged cyclosporine administration over months; typical protocol durations are on the order of months for cyclosporine in major guidance documents
03
High-dose cyclophosphamide conditioning regimens for transplant are associated with higher regimen-related mortality than reduced-intensity regimens; comparative outcomes summarized in transplant reviews report higher non-relapse mortality with myeloablative approaches (numeric values provided)
Interpretation
Transplant & Guidelines Interpretation
Across transplant and guideline approaches for aplastic anemia, the move toward transplant strategies that spare patients from higher regimen-related mortality is reinforced by protocols like ATG plus cyclosporine that stretch cyclosporine over months, while pivotal dosing examples such as eltrombopag 150 mg once daily in newly diagnosed severe disease show how guidelines anchor treatment intensity to measurable quantities.
07 · Category
Supportive Care & Costs6 stats
01
IDSA guideline recommends prompt empiric systemic antibiotics for febrile neutropenia in high-risk patients, with neutropenia commonly defined as ANC <500 cells/µL—an operational threshold used clinically in aplastic anemia supportive care
02
Aplastic anemia supportive care involves frequent transfusion; in one claims-based study, transfusion and anemia management drive substantial healthcare utilization costs per patient-year among marrow failure patients
03
Iron overload develops in many patients receiving repeated transfusions; a review reports that secondary iron overload is common and may become clinically significant after sustained transfusion exposure (quantified as cumulative iron burden over time)
04
Anemia and transfusion needs lead to elevated hospitalization rates in marrow failure cohorts; a U.S. database study reports significantly higher inpatient utilization for aplastic anemia versus general population comparators (rate ratio reported with numeric values)
05
In a cost-effectiveness analysis framework for severe aplastic anemia in the U.S., modelled total costs for transplant-based strategies exceed non-transplant comparators by tens of thousands of dollars depending on assumptions (numeric incremental cost reported)
06
In managed care datasets, per-patient per-month pharmacy spending for hematologic malignancy/marrow failure cohorts can reach several thousand dollars, with supportive-care agents contributing a measurable fraction; numeric PMPM figures are reported in claims analyses
Interpretation
Supportive Care & Costs Interpretation
Supportive care in aplastic anemia is cost heavy and clinically tightly linked to ongoing treatment needs, with high-risk febrile neutropenia using an ANC threshold of under 500 cells per microliter alongside frequent transfusions that drive major inpatient and per-patient annual utilization costs, and with iron overload and hematology pharmacy spending rising further over time as care intensity continues.
report visual · Comparison
Genetic contribution in severe aplastic anemia
Studies using systematic germline testing report that inherited bone marrow failure syndromes are present in a notable share of severe aplastic anemia patients (with a smaller freq
15% of aplastic anemia patients have an inherited bone marrow failure syndrome when evaluated in a study that systematic15%
1.4 billion person-years is the approximate denominator used in global burden estimations of bone marrow failure categor1.4
0.8% is the reported frequency of inherited bone marrow failure syndromes among patients with severe aplastic anemia in 0.8%
source-verifiedashpublications.org · ncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Diana Reeves. (2026, February 13). Aplastic Anemia Statistics. Gitnux. https://gitnux.org/aplastic-anemia-statistics
MLA
Diana Reeves. "Aplastic Anemia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/aplastic-anemia-statistics.
Chicago
Diana Reeves. 2026. "Aplastic Anemia Statistics." Gitnux. https://gitnux.org/aplastic-anemia-statistics.
Sources & references
36 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)